On the difficult fate of many Parkinson's patients wanted to make Tom Isaacs 2002 with his one-year trek around the entire coast of Britain's attention. Darmstadt, 13 October 2009 on the difficult fate of many Parkinson's patients wanted to Tom Isaacs 2002 with his one-year trek around the entire coast of Britain's attention. He then wrote a book about his journey. More information is housed here: Gunnar Peterson. Shake well before use\"British reports about the handling of the disease outbreak of, the side effects of the drugs, and his experiences on the trip. Today he advocates along with many sufferers a cure of the disease and has become the Foundation of the cure Parkinson's trust\"founded to promote dialogue between patients and the pharmaceutical industry. Tom Isaacs was just 27 years old, when he received the shattering diagnosis of Parkinson's disease.
A disease which usually only occurs at an advanced age. But when Isaac's body on a specific Parkinson's drug jumped on, the disturbing suspicion was to the Certainty. Since then the ambitious book author tries to deal aggressively with the heavy neurosis and not excessively limit by the tremors and the muscle stiffness that occur when decreasing effect of the drugs. On the swaying Millennium Bridge in London Tom Isaacs in April 2002 to the main tour his life went on: he circumnavigated the entire British Isles once and put back the enormous distance of 7,300 km in 365 days. When he reached the Millennium Bridge again after a year of wandering, Sir Richard Nichols, former Lord Mayor of London, to this legendary performance congratulated him. Nichols also suffering from Parkinson's disease was inspired by Isaac's iron will and his decisiveness. \"Tom Isaacs himself his annual migration meant not only many unforgettable moments, but also the beginning of his worn by patients and non-profit foundation of the cure Parkinson's trust\". The main objective of the Foundation is to dialogue between the pharmaceutical industry and Parkinson's patients promote to promote the development of drugs against these neurodegenerative disease.